Syndax
  • Home
  • About Us
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Vision, Mission, and Values
  • Pipeline
    • Back
    • Pipeline
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Back
    • Clinical Trials
    • Revumenib Clinical Trials
      • Back
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Back
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Back
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Back
      • Financial Overview
      • SEC Filings
      • Annual Reports & Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Back
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • FAQs
    • Contact Us
  • Contact Us
Syndax
Contact Us
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Vision, Mission, and Values
  • Pipeline
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • FAQs
    • Contact Us
  • Join Us

Determined to realize a future in which people with cancer live longer and better than ever before.


  • What is SNDX-5613?
  • What is axatilimab?
  • What clinical trials is Syndax currently conducting?
  • Who is on the leadership team at Syndax?
  • Where can I see your product pipeline?
  • Where can I find the latest corporate presentation?
  • What is the vision of Syndax?
  • Is Syndax hiring?
  • How can my organization collaborate with Syndax?
  • What is entinostat?
Pipeline
Leadership
Clinical Trials
Publications

08.08.22

Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

08.02.22

Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022

06.16.22

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

06.13.22

Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer

© 2022 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • Investors
  • Career Opportunities